Newsroom

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Media Center

All
Media Highlights
Press Releases
Media

Can Geneticists Fight Disease by Targeting ‘Nurture’ Instead of ‘Nature’?

September 8, 2026

The New York Times

Read Now
Media

Scribe’s Genetic Editing Aims to Prevent Heart Attacks

July 27, 2026

Barron's

Read Now
Media

Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds

July 24, 2026

Fierce Biotech

Read Now
Media

Eli Lilly-Backed Scribe Therapeutics Soars 44% After IPO

July 24, 2026

Bloomberg News

Read Now
Media

Scribe Bets on a New Era of Gene Editing

July 24, 2026

Bloomberg Tech

Read Now
Media

Scribe prices upsized IPO before producing human efficacy data

July 24, 2026

Axios

Read Now
Press release

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

September 2, 2026

Read Now
Press release

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 1, 2026

Read Now
Press release

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

July 27, 2026

Read Now
Press release

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

July 23, 2026

Read Now
Press release

Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials

June 18, 2026

Read Now
Press release

Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose

May 28, 2026

Read Now
Blog

Publications